vs
Amphastar Pharmaceuticals, Inc.（AMPH）とSprinklr, Inc.（CXM）の財務データ比較。上の社名をクリックして会社を切り替えられます
Sprinklr, Inc.の直近四半期売上が大きい（$219.1M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.2倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 1.3%、差は12.0%）。Sprinklr, Inc.の前年同期比売上増加率が高い（9.2% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $19.8M）。過去8四半期でSprinklr, Inc.の売上複合成長率が高い（6.2% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Sprinklrは米国のSaaS企業で、顧客体験管理（CXM）プラットフォームの開発を事業の柱としている。同名の自社製品は、ソーシャルメディアマーケティング、ソーシャル広告、コンテンツ管理、チームコラボレーション、従業員アドボカシー、カスタマーサポート、ソーシャル調査・監視などの機能を統合し、企業の顧客体験管理を一貫して支援する。
AMPH vs CXM — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $219.1M |
| 純利益 | $24.4M | $2.9M |
| 粗利率 | 46.8% | 66.4% |
| 営業利益率 | 19.4% | 5.3% |
| 純利益率 | 13.3% | 1.3% |
| 売上前年比 | -1.8% | 9.2% |
| 純利益前年比 | -35.7% | -72.2% |
| EPS（希薄化後） | $0.51 | $0.01 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $219.1M | ||
| Q3 25 | $191.8M | $212.0M | ||
| Q2 25 | $174.4M | $205.5M | ||
| Q1 25 | $170.5M | $202.5M | ||
| Q4 24 | $186.5M | $200.7M | ||
| Q3 24 | $191.2M | $197.2M | ||
| Q2 24 | $182.4M | $196.0M | ||
| Q1 24 | $171.8M | $194.2M |
| Q4 25 | $24.4M | $2.9M | ||
| Q3 25 | $17.4M | $12.6M | ||
| Q2 25 | $31.0M | $-1.6M | ||
| Q1 25 | $25.3M | $98.7M | ||
| Q4 24 | $38.0M | $10.5M | ||
| Q3 24 | $40.4M | $1.8M | ||
| Q2 24 | $37.9M | $10.6M | ||
| Q1 24 | $43.2M | $21.1M |
| Q4 25 | 46.8% | 66.4% | ||
| Q3 25 | 51.4% | 68.2% | ||
| Q2 25 | 49.6% | 69.5% | ||
| Q1 25 | 50.0% | 71.0% | ||
| Q4 24 | 46.5% | 71.2% | ||
| Q3 24 | 53.3% | 72.6% | ||
| Q2 24 | 52.2% | 73.9% | ||
| Q1 24 | 52.4% | 75.5% |
| Q4 25 | 19.4% | 5.3% | ||
| Q3 25 | 13.2% | 7.7% | ||
| Q2 25 | 24.2% | -0.9% | ||
| Q1 25 | 21.9% | 5.2% | ||
| Q4 24 | 24.2% | 3.9% | ||
| Q3 24 | 29.8% | -0.0% | ||
| Q2 24 | 30.3% | 2.9% | ||
| Q1 24 | 27.9% | 9.5% |
| Q4 25 | 13.3% | 1.3% | ||
| Q3 25 | 9.0% | 5.9% | ||
| Q2 25 | 17.8% | -0.8% | ||
| Q1 25 | 14.8% | 48.7% | ||
| Q4 24 | 20.4% | 5.2% | ||
| Q3 24 | 21.1% | 0.9% | ||
| Q2 24 | 20.8% | 5.4% | ||
| Q1 24 | 25.1% | 10.9% |
| Q4 25 | $0.51 | $0.01 | ||
| Q3 25 | $0.37 | $0.05 | ||
| Q2 25 | $0.64 | $-0.01 | ||
| Q1 25 | $0.51 | $0.35 | ||
| Q4 24 | $0.74 | $0.04 | ||
| Q3 24 | $0.78 | $0.01 | ||
| Q2 24 | $0.73 | $0.04 | ||
| Q1 24 | $0.81 | $0.07 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $189.6M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $558.1M |
| 総資産 | $1.6B | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $189.6M | ||
| Q3 25 | $276.2M | $125.4M | ||
| Q2 25 | $231.8M | $126.4M | ||
| Q1 25 | $236.9M | $145.3M | ||
| Q4 24 | $221.6M | $93.2M | ||
| Q3 24 | $250.5M | $119.1M | ||
| Q2 24 | $217.8M | $126.8M | ||
| Q1 24 | $289.6M | $164.0M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $558.1M | ||
| Q3 25 | $776.7M | $543.4M | ||
| Q2 25 | $757.5M | $639.8M | ||
| Q1 25 | $751.3M | $612.1M | ||
| Q4 24 | $732.3M | $497.0M | ||
| Q3 24 | $727.7M | $469.0M | ||
| Q2 24 | $713.3M | $610.9M | ||
| Q1 24 | $672.4M | $679.7M |
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.7B | $1.1B | ||
| Q2 25 | $1.6B | $1.2B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.6B | $970.3M | ||
| Q3 24 | $1.5B | $983.8M | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.6B | $1.2B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $20.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $19.8M |
| FCFマージンFCF / 売上 | 13.4% | 9.0% |
| 設備投資強度設備投資 / 売上 | 4.5% | 0.1% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 6.87× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $142.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $20.0M | ||
| Q3 25 | $52.6M | $34.8M | ||
| Q2 25 | $35.6M | $83.8M | ||
| Q1 25 | $35.1M | $5.4M | ||
| Q4 24 | $29.0M | $9.2M | ||
| Q3 24 | $60.0M | $21.3M | ||
| Q2 24 | $69.1M | $41.7M | ||
| Q1 24 | $55.3M | $17.3M |
| Q4 25 | $24.6M | $19.8M | ||
| Q3 25 | $47.2M | $34.4M | ||
| Q2 25 | $25.0M | $83.5M | ||
| Q1 25 | $24.4M | $4.6M | ||
| Q4 24 | $16.6M | $8.2M | ||
| Q3 24 | $46.2M | $19.8M | ||
| Q2 24 | $63.1M | $39.2M | ||
| Q1 24 | $46.5M | $15.2M |
| Q4 25 | 13.4% | 9.0% | ||
| Q3 25 | 24.6% | 16.2% | ||
| Q2 25 | 14.3% | 40.6% | ||
| Q1 25 | 14.3% | 2.3% | ||
| Q4 24 | 8.9% | 4.1% | ||
| Q3 24 | 24.1% | 10.1% | ||
| Q2 24 | 34.6% | 20.0% | ||
| Q1 24 | 27.1% | 7.9% |
| Q4 25 | 4.5% | 0.1% | ||
| Q3 25 | 2.8% | 0.2% | ||
| Q2 25 | 6.1% | 0.1% | ||
| Q1 25 | 6.3% | 0.4% | ||
| Q4 24 | 6.7% | 0.5% | ||
| Q3 24 | 7.2% | 0.8% | ||
| Q2 24 | 3.3% | 1.3% | ||
| Q1 24 | 5.1% | 1.1% |
| Q4 25 | 1.35× | 6.87× | ||
| Q3 25 | 3.03× | 2.76× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | 0.05× | ||
| Q4 24 | 0.76× | 0.88× | ||
| Q3 24 | 1.48× | 11.58× | ||
| Q2 24 | 1.82× | 3.92× | ||
| Q1 24 | 1.28× | 0.82× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
CXM
| License And Service | $190.3M | 87% |
| Professional Services | $28.8M | 13% |
